BioSpace News Archive

Retailer’s new technology makes getting prescriptions and vaccines easier while limiting touchpoints between customers and team members

Radiation Business Solutions (RBS) announced that they reached an agreement to purchase RADMAX, Inc., a radiation oncology medical billing company headquartered in Tyler, TX , effective August 31, 2020 . RBS also announced the development of their new, quality-driven radiation oncology network, VidaCore. “In light of th

SIWA Therapeutics, Inc., has announced positive results that support further development of its monoclonal antibody, 318H, as a broad-spectrum antiviral drug.

BERG, a clinical-stage biotech that employs artificial intelligence (AI) to investigate diseases and develop innovative treatments, today announced two major medical/clinical research developments on pancreatic ductal adenocarcinoma (PDAC) to be presented virtually at the European Society for Medical Oncology (ESMO) 2020 Congress taking place from September 19-21, 2020.

Kala Pharmaceuticals, Inc., announced that the Company granted non-statutory stock options to a new employee as inducement awards outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635.

Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that on September 17, 2020,

OpGen, Inc. (Nasdaq: OPGN, “OpGen” or the “Company”) announced today that it has changed the venue of its 2020 Annual Meeting of Stockholders due to continuing health and safety considerations arising from the COVID-19 pandemic.

The CMA agrees with Canada’s Premiers that additional federal funding is urgently needed to address the immense pressures on our health care system.

Sumitomo Dainippon Pharma Oncology, Inc., a developer of novel cancer therapeutics, today presented new data from the ongoing Phase 1 study evaluating dubermatinib (TP-0903), an AXL kinase inhibitor, in patients with advanced solid tumors.

Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced updated clinical results from its Phase 2 study evaluating sitravatinib in combination with nivolumab (OPDIVO®) in patients with advanced or metastatic urothelial carcinoma.